• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Citius Oncology Inc.

    9/19/25 5:12:16 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTOR alert in real time by email
    S-8 1 ea0257803-s8_citius.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on September 19, 2025

    Registration No. 333-              

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

      

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     CITIUS ONCOLOGY, INC.

    (Exact name of registrant as specified in its charter) 

     

     Delaware   99-4362660
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    11 Commerce Drive, First Floor, Cranford New Jersey   07016
    (Address of principal executive offices)   (Zip code)

     

    Citius Oncology, Inc. 2023 Omnibus Stock Incentive Plan

    Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan

    (Full title of the plans)

     

    Leonard Mazur

    Chairman and Chief Executive Officer

    11 Commerce Drive, First Floor

    Cranford, New Jersey 07016 

    Telephone: (908) 967-6677

     (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    With copies to:

    Lorna A. Knick, Esq.

    Alexander M. Donaldson, Esq.

    Christopher P. Agoranos, Esq.

    Wyrick Robbins Yates & Ponton LLP

    4101 Lake Boone Trail, Suite 300

    Raleigh, North Carolina 27607

    Telephone: (919) 781-4000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.

     

    Information required by Item 1 is included in documents sent or given by Citius Oncology, Inc. (the “Registrant”) to participants in the 2023 Omnibus Stock Incentive Plan or the 2024 Omnibus Stock Incentive Plan (collectively, the “Plans”), as applicable, as covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

     

    Item 2. Registrant Information and Employee Plan Annual Information.

     

    The written statement required by Item 2 is included in documents sent or given by the Registrant to participants in the Plans covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed with the Securities and Exchange Commission (the “Commission”) are hereby incorporated by reference in this Registration Statement (other than portions of those documents furnished or otherwise not deemed filed):

     

    ●the Registrant’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the Commission on December 27, 2024, as amended on January 27, 2025;

     

    ●the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2024, filed with the Commission pursuant to Section 13(a) of the Exchange Act on February 14, 2025;

     

    ●the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, filed with the Commission pursuant to Section 13(a) of the Exchange Act on May 14, 2025;

     

    ●the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, filed with the Commission pursuant to Section 13(a) of the Exchange Act on August 12, 2025; 

     

    ●the Registrant’s Current Reports on Form 8-K, filed with the Commission on November 12, 2024, and January 6, January 7, 2025, February 6, February 14, April 3, April 25, June 17, June 27, July 18, August 18, September 10, and September 19, 2025; and

     

    ●the description of the Company’s Common Stock contained in the Registration Statement on Form 8-A (File No. 001-41534), filed with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) on October 13, 2022, as updated by the description of the Registrant’s common stock contained in Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, including any amendments or reports filed for the purpose of updating such description.

     

    In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. However, any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the Commission, including without limitation any information furnished pursuant to Item 2.02 or 7.01 of Form 8-K or certain exhibits furnished pursuant to Item 9.01 of Form 8-K, shall not be deemed to be incorporated by reference in this Registration Statement.

     

    Any statement in a document incorporated by reference or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     II-1

     

     

    Item 4. Description of Securities.

     

    Not applicable. The class of securities to be offered is registered under Section 12 of the Exchange Act.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Subsection (a) of Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”) empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful.

     

    Subsection (b) of Section 145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    Section 145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section 145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person’s heirs, executors and administrators. Section 145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section 145.

     

    Section 102(b)(7) of the DGCL provides that a corporation’s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit.

     

     II-2

     

     

    Additionally, our certificate of incorporation limits the liability of our directors to the fullest extent permitted by the DGCL, and our Bylaws provide that we will indemnify them to the fullest extent permitted by such law.

     

    We maintain a general liability insurance policy that covers certain liabilities of directors and officers of the Company arising out of claims based on acts or omissions in their capacities as directors or officers.

     

    Item 7. Exemption From Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    EXHIBIT NO.   DESCRIPTION   FILE HEREWITH   FORM   EXHIBIT   FILING DATE
    .1   Certificate of Incorporation of Citius Oncology, Inc.       8-K   3.1   8/16/2024
                         
    4.2   Certificate of Amendment to the Certificate of Incorporation of Citius Oncology, Inc., filed with the Secretary of State of the State of Delaware on April 7, 2025.       Schedule 14C  

    A

      02/24/2025
                         
    4.3   Bylaws of Citius Oncology, Inc.       8-K   3.2   8/16/2024
                         
    5.1   Opinion of Wyrick Robbins Yates & Ponton LLP.   X            
                         

    23.1

      Consent of Wolf & Company, P.C.   X            
                         
    23.2   Consent of Wyrick Robbins Yates & Ponton LLP (included in Exhibit 5.1).   X            
                         
    24.1   Power of Attorney (included on signature page to this Registration Statement on Form S-8).   X            
                         
    99.1   Citius Oncology, Inc. 2023 Omnibus Stock Incentive Plan.       10-K   10.3   12/27/2024
                         
    99.2   Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan.       8-K   10.5   8/5/2024
                         
    99.3   Amendment to the Citius Oncology, Inc. 2024 Omnibus Stock Incentive Plan, effective September 19, 2025.       8-K   10.1   9/19/2025
                         
    107   Filing fee table.    X            

     

     II-3

     

     

    Item 9. Undertakings.

     

    (a)The undersigned Registrant hereby undertakes:

     

    (1)To file during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii)To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Exhibit 107 (Filing Fee Table) in the effective Registration Statement;

     

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cranford, New Jersey on September 19, 2025.

     

      Citius Oncology, Inc.
         
      By: /s/ Leonard Mazur
        Leonard Mazur
        Chief Executive Officer and Chairman
        (Principal Executive Officer)

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Leonard Mazur and Jaime Bartushak, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name     Title   Date  
               
    /s/ Leonard Mazur     Chief Executive Officer and Director   September 19, 2025  
    Leonard Mazur     (Principal Executive Officer)    
               
    /s/ Jaime Bartushak     Chief Financial Officer and Treasurer   September 19, 2025  
    Jaime Bartushak     (Principal Financial Officer and Principal Accounting Officer))    
               
    /s/ Myron Holubiak     Secretary and Director     September 19, 2025  
    Myron Holubiak        
               
    /s/ Suren Dutia     Director   September 19, 2025  
    Suren Dutia        
               
    /s/ Eugene Holuka     Director   September 19, 2025  
    Eugene Holuka        
               
    /s/ Joel Mayersohm     Director   September 19, 2025  
    Joel Mayersohm        
               
    /s/ Dennis McGrath     Director   September 19, 2025  
    Dennis McGrath        
               
    /s/ Robert Smith     Director   September 19, 2025  
    Robert Smith        
               
    /s/ Carol Webb     Director   September 19, 2025  
    Carol Webb        

     

     II-5

     

     

    Get the next $CTOR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTOR

    DatePrice TargetRatingAnalyst
    9/23/2025$6.00Hold → Buy
    Maxim Group
    11/27/2024$3.00Buy
    Maxim Group
    More analyst ratings

    $CTOR
    SEC Filings

    View All

    SEC Form DEF 14A filed by Citius Oncology Inc.

    DEF 14A - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    9/26/25 4:30:39 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Citius Oncology Inc.

    S-8 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    9/19/25 5:12:16 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Oncology Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

    8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    9/19/25 5:00:51 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citius Oncology upgraded by Maxim Group with a new price target

    Maxim Group upgraded Citius Oncology from Hold to Buy and set a new price target of $6.00

    9/23/25 7:47:11 AM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Citius Oncology with a new price target

    Maxim Group initiated coverage of Citius Oncology with a rating of Buy and set a new price target of $3.00

    11/27/24 8:17:22 AM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

    CRANFORD, N.J., Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced the closing of its previously announced registered direct offering and concurrent private placement of an aggregate of 5,142,858 shares of common stock and unregistered warrants to purchase up to an aggregate of 5,142,858 shares of common stock. The combined effective offering price for each share of common stock and accompanying warrant was $1.75. The warrants have an ex

    9/10/25 4:30:00 PM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

    CRANFORD, N.J., Sept. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,142,858 shares of common stock in a registered direct offering. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 5,142,858 shares of common stock. The combined effective offering price for eac

    9/9/25 8:30:00 AM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

    Proprietary model informs targeted sales and marketing strategies with feedback loop that augments precision and impact of targeting and engagement CRANFORD, N.J., Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has deployed an innovative AI platform to support its commercial team with advanced data analytics and insights ahead of the anticipated launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL). The plat

    8/22/25 8:47:00 AM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Czuczman Myron was granted 825,000 shares (SEC Form 4)

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    9/23/25 4:10:20 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Mazur Leonard L was granted 1,700,000 shares (SEC Form 4)

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    9/23/25 4:10:23 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Secretary Holubiak Myron Z was granted 950,000 shares (SEC Form 4)

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    9/23/25 4:10:26 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    Leadership Updates

    Live Leadership Updates

    View All

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CTOR
    Financials

    Live finance-specific insights

    View All

    Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

    Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

    12/27/24 5:00:00 PM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

    SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

    11/6/24 5:08:07 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

    SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

    9/5/24 9:23:54 AM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Citius Oncology Inc.

    SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

    8/16/24 4:34:29 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care